The company will use the capital, which follows an internal fundraising that raised $24m in January 2015 to fund DNAe’s acquisition of Albuquerque, USA-based nanoMR, Inc. (now DNA Electronics, Inc.), for the final development stages of its point-of-need test for serious blood infections. This will include clinical trials targeted for 2016 and product launch in 2017.
Led by Prof. Chris Toumazou, Executive Chairman, DNAe is applying its Genalysis® semiconductor DNA sequencing technology to develop a rapid in vitro diagnostic for serious blood infections that lead to sepsis.
The test integrates DNA Electronics’ novel Pathogen Capture System technology with DNAe’s Genalysis® platform, to provide a complete blood-to-result diagnostic solution with actionable results in 2-3 hours.
The company is backed by international investors including major shareholder Genting Berhad, a Malaysian-based global investor with a portfolio of life sciences companies.